Something’s changing in the fight against amyotrophic lateral sclerosis (ALS).

For years, this neurodegenerative disease has been synonymous with uncertainty, suffering and limited treatment options. But in recent times, scientific breakthroughs have been painting a different picture: for the first time, innovative therapies, specialised start-ups and initiatives are emerging that offer hopeful results which could truly transform the future of ALS.

This collective drive comes not only from large firms and pharmaceutical companies. It’s also taking shape in universities, hospitals and research centres around the world, where researchers, doctors and experts are working day after day with the same goal: to understand ALS and come closer to finding a cure.

“Even when we dispose of it in the right bin, much of the plastic produced in the world ends up in landfill and less than 10% is recycled. With the action of the sun, wind and waves it fragments, releasing microplastics into the environment“, explains Emma Calikanzaros, a researcher in environmental epidemiology and microplastics.

These tiny bits of plastic, which are also released from textiles and cosmetics, travel through rivers, seas and air to reach remote areas of the planet. Studying them is not easy, as they are particles ranging from 0.1 to 5 millimeters, very diverse in shape, size, and composition. “Globally standardised methods to measure their concentration are still lacking but need to be developed.

You’re at a museum. You pass by dozens of paintings until one, you don’t quite know why, catches your attention. It’s not just what you see; it’s what it makes you feel.

Now imagine another scene. A laboratory and, under the microscope, an image. Cells stained with impossible colours, shapes that look like abstract landscapes. You’re not in the Prado but something in that image fascinates you. An image that, moreover, may be the key to a new scientific discovery.

While a researcher creates knowledge, an artist arouses emotions. But the boundaries aren’t always so clear.

Today we talk to Eloísa Herrera,

When Margaret Keenan, a 90-year-old woman from Coventry (UK), received the first COVID-19 vaccine, it was just 11 months after the discovery of the virus that caused it and less than 9 months after a pandemic had been declared. It was the 8th of December 2020 and biomedicine was setting an all-time record. By comparison, it took 5 years to develop and approve the Ebola vaccine and 7 years for measles. This unprecedented speed was made possible by a combination of factors, including exceptional funding and global cooperation, but one of these factors made all the difference: RNA technology.

Far from being a one-off solution, this breakthrough has opened the door to a new generation of therapies based on RNA (a key molecule in essential processes such as protein synthesis) that are revolutionising medicine by offering more versatile,

“Clinical trials aren’t only a tool for research but also represent a real possibility of treatment for patients who’ve exhausted many other options”. This is the premise with which Elena Garralda, Director of UITM-CaixaResearch at VHIO, validates each of the new therapies promoted by this research unit.

One example of this is the clinical trial for the European project PragmaTIL, led by VHIO. With the participation of 12 institutions from 6 countries, including “la Caixa” Foundation, this trial has treated the first patient with an innovative immunotherapy. Its aim? To improve the care of people with resistant tumours, reducing the treatment’s toxicity but without it losing any efficacy.